VVUS had a 2.2Billion MKTCAP too once. Until sales began and then it got crushed over 60% down.
Whatever the eventual success of Belviq will be, it is an almost slam dunk that initial sales will not come anywhere close to the current analyst estimates that are needed to justify the current 2.2B mktcap. This is simply the sad truth. Expect a crush down closer to the current VVUS mktcap levels within 1 month after launch. That would put it at about 6 bucks.
It had a 3.8 billion marketcap which was incredible for such a bad dangerous drug. If ARNA got up to only 3 billion it would be 15 a share. Think about that shorty. It would still be 20% under what that VVUS turd got up at. AND ARNA has international rights and sales AND a partner.
It always amazes me how wallstreet pumps the bad stocks and keeps the true gems undervalued. ARNA should be at 15 right now.